New insider activity at Roivant Sciences ( (ROIV) ) has taken place on April 10, 2026.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Roivant Sciences’ Chief Accounting Officer, Jennifer Humes, recently unloaded 13,538 shares of the company’s stock in a transaction totaling $384,073, signaling a notable insider move that may draw attention from investors tracking executive trading activity.
Recent Updates on ROIV stock
Roivant Sciences shares reacted to mixed pipeline news, as the company expanded brepocitinib into a seamless Phase 2b/3 trial for lichen planopilaris, reinforcing its rare dermato‑rheumatology strategy and adding a fourth late‑stage indication. At the same time, failed Phase 3 thyroid eye disease trials for batoclimab shifted focus toward next‑gen FcRn agent IMVT‑1402, while analysts’ targets reflected upside from upcoming pulmonary hypertension and uveitis readouts but also competitive and launch‑execution risks around brepocitinib.
Spark’s Take on ROIV Stock
According to Spark, TipRanks’ AI Analyst, ROIV is a Neutral.
ROIV scores as a moderate-risk biotech: strong balance-sheet positioning and a constructive clinical/regulatory catalyst setup (including Priority Review) support the score, but persistent losses and ongoing cash burn weigh heavily. Technicals are neutral-to-slightly constructive, while valuation remains pressured due to negative earnings and no dividend support.
To see Spark’s full report on ROIV stock, click here.
More about Roivant Sciences
YTD Price Performance: 31.24%
Average Trading Volume: 6,213,120
Technical Sentiment Signal: Buy
Current Market Cap: $20.38B